Community hub
Recent from talks
Contribute something
Nothing was collected or created yet.
LSM-775
View on Wikipedia
 | |
| Clinical data | |
|---|---|
| Other names | LSM775; LSM; SLM; N-Morpholinyllysergamide; Lysergic acid morpholide; LA-Morph; LA-Morpholide; Morpholine lysergamide; 6-Methyl-8β-(morpholin-4-ylcarbonyl)-9,10-didehydroergoline |
| Routes of administration | Oral |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H23N3O2 |
| Molar mass | 337.423 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
LSM-775, also known as N-morpholinyllysergamide or as lysergic acid morpholide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[2]
Use and effects
[edit]LSM-775 is less potent than LSD but is reported to have some LSD-like effects at doses ranging from 75 to 700 μg and a shorter duration.[3] It may only produce weak or threshold psychedelic effects in humans.[4] There are claimed to be fewer signs of cardiovascular stimulation and peripheral toxicity with LSM-775 compared to LSD.[3][dubious – discuss]
Interactions
[edit]Pharmacology
[edit]Pharmacodynamics
[edit]LSM-775 is a potent full agonist of the serotonin 5-HT1A receptor and a potent partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[4] It does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[4] However, LSM-775 can robustly increase head twitches if it is coadministered with the serotonin 5-HT1A receptor antagonist WAY-100635.[4] These findings indicate that serotonin 5-HT1A receptor activation suppresses the psychedelic-like effects of LSM-775.[4]
History
[edit]LSM-775 was first described in the scientific literature by Albert Hofmann and colleagues by 1955.[5]
See also
[edit]- Substituted lysergamide
- Non-hallucinogenic 5-HT2A receptor agonist
- Lysergic acid pyrrolidide (LPD-824)
- Lysergic acid piperidide (LSD-Pip)
- Lysergic acid azepane (LA-Azepane)
- Lysergic acid 2,4-dimethylazetidide (LA-SS-Az, LSZ)
References
[edit]- ^ "Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants" [Order of May 20, 2021 amending the order of February 22, 1990 setting the list of substances classified as narcotics]. www.legifrance.gouv.fr (in French). 20 May 2021.
- ^ Gogerty JH, Dille JM (July 1957). "Pharmacology of d-lysergic acid morpholide (LSM)". The Journal of Pharmacology and Experimental Therapeutics. 120 (3): 340–348. doi:10.1016/S0022-3565(25)23282-7. PMID 13476356.
- ^ a b Shulgin A, Shulgin A. "TiHKAL #26, LSD-25". Erowid.
- ^ a b c d e Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, et al. (February 2018). "Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)". Drug Testing and Analysis. 10 (2): 310–322. doi:10.1002/dta.2222. PMC 6230476. PMID 28585392.
- ^ Hofmann A, Stoll A (1955). "Amide der stereoisomeren Lysergsäuren und Dihydro-lysergsäuren. 38. Mitteilung über Mutterkornalkaloide" [Amides of stereoisomeric lysergic and dihydrolysergic acids. 38. Ergot alkaloids]. Helvetica Chimica Acta. 38 (2): 421–433. Bibcode:1955HChAc..38..421S. doi:10.1002/hlca.19550380207. ISSN 0018-019X. Retrieved 5 June 2025.